Source: Annual Congress 2002 - COPD - Drug therapy 1
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Vestbo, P. M. A. Calverley, R. Pauwels, P. Jones, N. B. Pride, A. Gulsvik, J. Anderson, J. B. Soriano, C. Maden, on Behalf of the TRISTAN Study Group (Hvidovre, Denmark; Liverpool, London, Greenford, United Kingdom; Gent, Belgium; Bergen, Norway). Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. Eur Respir J 2002; 20: Suppl. 38, 1570

Member's Comments

No comment yet.

Related content which might interest you: Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease Source: Eur Respir J 2004; 24: 1075 Year: 2004 Safety of salmeterol / fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease (COPD) for one year Source: Eur Respir J 2002; 20: Suppl. 38, 242s Year: 2002 The efficacy of formoterol in patients with chronic obstructive pulmonary disease (COPD) is not influenced by concomitant corticosteroid use Source: Eur Respir J 2001; 18: Suppl. 33, 515s Year: 2001 Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease Source: Eur Respir J 2003; 21: 74-81 Year: 2003 Bronchodilatory effects of formoterol in patients with chronic obstructive pulmonary disease (COPD) are not influenced by concomitant corticosteroid use Source: Eur Respir J 2001; 18: Suppl. 33, 514s Year: 2001 Reduction of exacerbations with salmeterol/fluticasone combination 50/500mcg bd in the treatment of chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2002; 20: Suppl. 38, 241s Year: 2002 Clinical effectiveness of nebulized budesonide in the treatment of acute asthma and exacerbations of chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2001; 18: Suppl. 33, 146s Year: 2001 Estimating the cost-effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease Source: Eur Respir J 2004; 24: Suppl. 48, 602s Year: 2004 The role of nebulised budesonide in the treatment of exacerbations of COPD Source: Eur Respir J 2007; 29: 660-667 Year: 2007 Triple therapy with Fluticasone furoate/Umeclidinium/Vilanterol compared with dual bronchodilation or triple therapy with inhaled corticosteroids/dual bronchodilation in patients with chronic obstructive pulmonary disease Source: Virtual Congress 2020 – Investigations of COPD Year: 2020 Efficacy of budesonide/formoterol in Chinese patients with chronic obstructive pulmonary disease Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II Year: 2008 Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations Source: Eur Respir J 2003; 21: 68-73 Year: 2003 Alveolar absorption and systemic bioactivity of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease Source: Eur Respir J 2004; 24: Suppl. 48, 13s Year: 2004 Additive benefits of tiotropium in asthmatics and in patients with asthma complicated chronic obstructive pulmonary disease Source: Eur Respir J 2007; 30: Suppl. 51, 546s Year: 2007 Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol Source: Eur Respir J 2004; 24: Suppl. 48, 291s Year: 2004 A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease Source: Eur Respir J 2002; 19: 217-224 Year: 2002 Efficacy of lasolvan in the treatment of patients with chronic obstructive pulmonary disease Source: Annual Congress 2009 - Drug effects in COPD Year: 2009 What is the optimal treatment strategy for chronic obstructive pulmonary disease exacerbations? Source: Eur Respir J 2002; 19: 928-935 Year: 2002 Rapid onset bronchodilation with formoterol or salbutamol in patients with chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2001; 18: Suppl. 33, 514s Year: 2001 Is there any point in treatment of patients with chronic obstructive pulmonary diseases with salmeterol and ipratropium bromide, alone and in combination? Source: Eur Respir J 2002; 20: Suppl. 38, 245s Year: 2002